Lead global clinical monitoring oversight at Olema Oncology to ensure high standards of quality and compliance in clinical trials.
Posted by employer 10 hours ago
First seen on Joblaze 6 hours ago
Last verified on the company career page 6 hours ago
What you'll build
Must have
Nice to have
Practical constraints
Requirements
Not disclosed in this posting: visa sponsorship.
Benefits
Joblaze summary
The Director of Clinical Monitoring Oversight at Olema Oncology is responsible for leading global clinical monitoring activities, ensuring high standards of quality and compliance across clinical trials. This role requires expertise in clinical operations, particularly in oncology, and a strong understanding of regulatory requirements and vendor management. Ideal candidates will have extensive experience in clinical monitoring oversight and team leadership, making this position suitable for seasoned professionals looking to impact cancer treatment development. Olema's focus on innovative therapies adds a layer of significance to the role.
Joblaze insights
Quick facts
From the original posting
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity.
Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP-3136 in combination with Bayer’s darolutamide in metastatic castration-resistant prostate cancer by the end of this year.
Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self-starters who bring consistency in our quest for the extraordinary every single day.
If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.
About the Role >>> Director, Clinical Monitoring Oversight
As the Director, Clinical Monitoring Oversight reporting to the Vice President, Clinical Operations you will provide strategic and operational leadership for global clinical monitoring oversight across Olema’s clinical programs. This role ensures that clinical monitoring, whether by internal teams, through Functional Service Providers (FSPs), or outsourced to Clinical Research Organizations (CROs), is executed with high standards of quality and consistency while maintaining compliance with GCP regulations. The Director oversees Olema’s Clinical Monitoring Oversight Leads, regional monitoring and oversight teams, clinical service provider/FSP provider, and site performance. This role will develop and implement global monitoring oversight strategies and standards for Olema’s clinical monitoring execution, driving operational excellence, data integrity, and inspection readiness across all trials with an emphasis on risk-based, data driven processes. The role will adapt to evolving organizational structures, monitoring delivery models, and clinical development needs as Olema's portfolio and operational requirements change.
This role is based out of our San Francisco or Cambridge office and will require 10-20% travel.
Your work will primarily encompass:
Knowledge:
Experience:
Attributes:
The base pay range for this position is expected to be $235,000 - $250,000 annually, however the base pay offered may vary depending on location, market, job related knowledge, skills and capabilities, and experience. The total compensation package for this position also includes equity, bonus, and benefits.
#LI-MT1
Important Information >>>
Standard company text repeated across Olema Oncology's postings is omitted here.